| pubmed-article:9020292 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9020292 | lifeskim:mentions | umls-concept:C0043210 | lld:lifeskim |
| pubmed-article:9020292 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:9020292 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:9020292 | lifeskim:mentions | umls-concept:C0039902 | lld:lifeskim |
| pubmed-article:9020292 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:9020292 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:9020292 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9020292 | pubmed:dateCreated | 1997-2-27 | lld:pubmed |
| pubmed-article:9020292 | pubmed:abstractText | 6-Thioguanine (6-TG) is a purine analog that has marked variability in plasma concentration after oral administration. Following the development of a multiple-day i.v. regimen, we performed a phase II trial of this agent as first-line chemotherapy in women with metastatic breast cancer. Forty-one patients with measurable (31 patients) or evaluable (10 patients) disease were entered into this trial. 6-TG was administered i.v. over a 10 min period daily for 5 consecutive days, with a planned cycle length of 35 days. The daily dosage level was 55 mg/m2 in the first 15 patients, but this was increased to 65 mg/m2 in the remaining patients due to inadequate myelosuppression at the lower dose. Six patients, all with measurable disease, achieved a complete response (CR) (two patients) or a partial response (PR) (four patients). Three responses occurred at the 55 mg/m2 level and three at the 65 mg/m2 level. The 95% confidence interval (CI) for the true response rate among patients with measurable disease was 6-39%. The median time to progression was 140 days and median survival time was 460 days. The regimen was well tolerated. We conclude that 6-TG, as given in this study, has limited activity as first-line chemotherapy for women with metastatic breast cancer. | lld:pubmed |
| pubmed-article:9020292 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9020292 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9020292 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9020292 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9020292 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9020292 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9020292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9020292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9020292 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9020292 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9020292 | pubmed:issn | 0277-3732 | lld:pubmed |
| pubmed-article:9020292 | pubmed:author | pubmed-author:IngleJ NJN | lld:pubmed |
| pubmed-article:9020292 | pubmed:author | pubmed-author:TwitoD IDI | lld:pubmed |
| pubmed-article:9020292 | pubmed:author | pubmed-author:SumanV JVJ | lld:pubmed |
| pubmed-article:9020292 | pubmed:author | pubmed-author:MarschkeR... | lld:pubmed |
| pubmed-article:9020292 | pubmed:author | pubmed-author:WindschitlH... | lld:pubmed |
| pubmed-article:9020292 | pubmed:author | pubmed-author:KrookJ EJE | lld:pubmed |
| pubmed-article:9020292 | pubmed:author | pubmed-author:MaillardJ AJA | lld:pubmed |
| pubmed-article:9020292 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9020292 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:9020292 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9020292 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9020292 | pubmed:pagination | 69-72 | lld:pubmed |
| pubmed-article:9020292 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:meshHeading | pubmed-meshheading:9020292-... | lld:pubmed |
| pubmed-article:9020292 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9020292 | pubmed:articleTitle | Evaluation of intravenous 6-thioguanine as first-line chemotherapy in women with metastatic breast cancer. | lld:pubmed |
| pubmed-article:9020292 | pubmed:affiliation | Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. | lld:pubmed |
| pubmed-article:9020292 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9020292 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9020292 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9020292 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
